* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download What is gene therapy?
Saethre–Chotzen syndrome wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Zinc finger nuclease wikipedia , lookup
Oncogenomics wikipedia , lookup
DNA vaccination wikipedia , lookup
Genome evolution wikipedia , lookup
Public health genomics wikipedia , lookup
Point mutation wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Genomic library wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Gene desert wikipedia , lookup
Adeno-associated virus wikipedia , lookup
Genome editing wikipedia , lookup
Gene nomenclature wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Gene expression programming wikipedia , lookup
Genetic engineering wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
History of genetic engineering wikipedia , lookup
Genome (book) wikipedia , lookup
Gene expression profiling wikipedia , lookup
Helitron (biology) wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Microevolution wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Gene therapy wikipedia , lookup
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST) COURSE CONTENTS GENE THERAPY Introduction to gene therapy Delivery of Therapeutic Genes Gene Therapy Targets Delivery Modes Steps in Gene Therapy Gene Therapy Viral & Non Viral vectors Liposomes COURSE CONTENTS Cell bases therapies Cancer gene therapy Gene therapy in plants Ethical issues in gene therapy Therapeutic Gene Regulation Control of therapeutic gene expression Prospects for gene therapy GENE THERAPY Any procedure intended to treat or alleviate disease by genetically modifying the cells of a patient History of gene therapy 1930’s “genetic engineering” - plant/animal breeding 60’s First ideas of using genes therapeutically 50’s-70’s Gene transfer developed 70’s-80’s Recombinant DNA technology 1990 First GT in humans (ADA deficiency) 2001 596 GT clinical trials (3464 patients) What is gene therapy? Why is it used? • Gene therapy is the application of genetic principles in the treatment of human disease • Gene therapy = Introduction of genetic material into normal cells in order to: – counteract the effect of a disease gene or – introduce a new function • GT is used to correct a deficient phenotype so that sufficient amounts of a normal gene product are synthesized to improve a genetic disorder • Can be applied as therapy for cancers, inherited disorders, infectious diseases, immune system disorders Amenability to gene therapy Mode of inheritance Identity of molecular defect Nature of mutation product Accessibility of target cells and amenability to cell culture Size of coding DNA Control of gene expression Gene Therapy First gene therapy trial for ADA deficiency -1990 GENE THERAPY Delivery mechanism Ex vivo In vivo Type of cells modified Germ-line cells Somatic cells Mechanism of modification Gene augmentation/supplementation Gene replacement Targeted inhibition of gene expression Targeted killing of specific cells Three types of gene therapy: • Monogenic gene therapy • Provides genes to encode for the production of a specific protein • Cystic fibrosis, Muscular dystrophy, Sickle cell disease, Haemophilia, SCID • Suicide gene therapy • Provide ‘suicide’ genes to target cancer cells for destruction • Cancer • Antisense gene therapy • Provides a single stranded gene in an’antisense’ (backward) orientation to block the production of harmful proteins • AIDS/HIV TYPES OF CELLS MODIFIED Germ-line gene therapy Modification of gametes, zygote or early embryo Permanent and transmissible Banned due to ethical issues Somatic cell gene therapy Modification of somatic cells, tissues etc Confined to the patient Getting genes into cells • In vivo versus ex vivo – In vivo = intravenous or intramuscular or noninvasive (‘sniffable’) – Ex vivo = hepatocytes, skin fibroblasts, haematopoietic cells (‘bioreactors’) • Gene delivery approaches – Physical methods – Non-viral vectors – Viral vectors In vivo techniques In vivo techniques usually utilize viral vectors Virus = carrier of desired gene Virus is usually “crippled” to disable its ability to cause disease Viral methods have proved to be the most efficient to date Many viral vectors can stable integrate the desired gene into the target cell’s genome – Problem: Replication defective viruses adversely affect the virus’ normal ability to spread genes in the body • Reliant on diffusion and spread • Hampered by small intercellular spaces for transport • Restricted by viral-binding ligands on cell surface therefore cannot advance far. DELIVERY MECHANISMS (In vivo) (ex vivo) VECTORS IN GT • Viral • • • • RetroAdenoAdeno-associatedHerpes simplex- • Non-viral • Naked DNA/Plasmid • liposomes Viral vectors “Viruses are highly evolved natural vectors for the transfer of foreign genetic information into cells” But to improve safety, they need to be replication defective Viral vectors Compared to naked DNA, virus particles provide a relatively efficient means of transporting DNA into cells, for expression in the nucleus as recombinant genes (example = adenovirus). [ Viral vectors Retroviruses – eg Moloney murine leukaemia virus (Mo-MuLV) – Lentiviruses (eg HIV, SIV) • Adenoviruses • Herpes simplex • Adeno-associated viruses (AAV) Engineering a virus into a viral vector Packaging Therapeutic gene Vector DNA Helper DNA wildtype virus essential viral genes replication proteins Packaging cell structural proteins Viral vector Gene transfer Vector uncoating vector Episomal vector Target cell Integrated expression cassette Therapeutic mRNA and protein Delivery System of Choice = Viral Vectors A. Rendering virus vector harmless Remove harmful genes “cripple” the virus Example – removal of env gene virus is not capable of producing a functional envelope Vectors needed in very large numbers to achieve successful delivery of new genes into patient’s cells Vectors must be propagated in large numbers in cell culture (109) with the aid of a helper virus Delivery System of Choice = Viral Vectors B. Integrating versus Non-Integrating Viruses • Integrating viruses – Retrovirus (e.g. murine leukemia virus) – Adeno-associated virus (only 4kbp accommodated) – Lentivirus • Non-Integrating viruses – – – – Adenovirus Alphavirus Herpes Simplex Virus Vaccinia Adenovirus Advantages • High transduction efficiency • Insert size up to 8kbHigh viral titer (1010-1013) • Infects both replicating and differentiated cells Disadvantages • Expression is transient (viral DNA does not integrate) • Viral proteins can be expressed in host following vector administration • In vivo delivery hampered by host immune response Herpes Simplex Virus Advantages • Large insert size • Could provide long- term CNS gene expression • High titer Disadvantages • System currently under development • Current vectors provide transient expression • Low transduction efficiency Ex vivo • Ex vivo manipulation techniques – Electroporation – Liposomes – Calcium phosphate – Gold bullets (fired within helium pressurized gun) – Retrotransposons (jumping genes – early days) – Human artificial chromosomes Electroporation Ex vivo Electroporation Risks Factors gene therapy Adverse response to the vector Insertional mutatgenesis resulting in malignant neoplasia Insertional inactivation of an essential gene Viruses may infect surrounding health tissues Overexpression of the inserted gene may lead to so much protein that it may become harmful The End